Two American states have now committed tens of millions of dollars to ibogaine research, and the reason is simple: veterans are demanding it. In December 2025, Texas awarded $50 million to a consortium led by UTHealth Houston and the University of Texas Medical Branch at Galveston to conduct FDA-approved clinical trials studying ibogaine's potential to treat PTSD, opioid addiction, and traumatic brain injury. Arizona followed suit shortly after, appropriating funding for similar trials focused on veterans and first responders.
These aren't modest pilot programs or symbolic gestures. Texas's $50 million investment represents the largest single state commitment to psychedelic research in US history. The trials will be conducted under strict FDA oversight with the explicit goal of gathering data that could support eventual federal approval. What's remarkable about this development is how it happened.
Unlike most medical research initiatives, which are typically driven by pharmaceutical companies or academic institutions, the ibogaine push has been led almost entirely by veterans. Many of them traveled to Mexico, Costa Rica, or Canada for treatment after conventional therapies failed.
They returned with dramatic improvements — reductions in PTSD symptoms, elimination of suicidal ideation, freedom from opioid dependence — and became advocates for domestic research.
They returned with dramatic improvements — reductions in PTSD symptoms, elimination of suicidal ideation, freedom from opioid dependence — and became advocates for domestic research. The political coalition supporting this work is equally unusual. In Texas, the legislation passed with overwhelming bipartisan support. In Arizona, a Republican-controlled legislature approved funding after former Senator Kyrsten Sinema, herself a recipient of ibogaine treatment in Mexico, championed the cause.
This is not a partisan issue. It's a veterans' issue. From a scientific standpoint, ibogaine presents unique challenges. Unlike psilocybin or MDMA, which have clearer safety profiles and well-established therapeutic protocols, ibogaine requires intensive medical monitoring.
Begin Your Journey
MindScape Retreat offers medically supervised ibogaine treatment in Cozumel, Mexico. Speak with our clinical team to learn if you are a candidate.
The treatment can last ten hours or more, involves significant cardiovascular stress, and must be administered in a clinical setting with emergency equipment on hand. This complexity has made US regulatory approval more difficult, even as evidence of efficacy has mounted. But the evidence is compelling. Observational studies from clinics in Mexico have shown that 70-80% of patients report significant reductions in opioid cravings for at least six months post-treatment.
Research on veterans has demonstrated dramatic reductions in PTSD symptoms, depression markers, and anxiety. The treatment appears to work through multiple mechanisms, including GDNF upregulation, opioid receptor reset, and profound neuroplastic changes. The Texas and Arizona trials will be the first to conduct this research under full FDA oversight on US soil. If the results match what observational data from international clinics has shown, it could create a pathway for ibogaine to become a legally available treatment option for veterans struggling with conditions that have proven resistant to conventional care.
For now, the majority of Americans seeking ibogaine treatment still travel to clinics in Mexico. MindScape Retreat in Cozumel, for example, has treated hundreds of patients over the past several years, many of them veterans. The medical protocols used in these clinics — pre-treatment cardiovascular screening, continuous EKG monitoring during treatment, physician supervision, and structured aftercare — are designed to mitigate risks while maximizing therapeutic benefit. The hope is that state-funded trials will eventually make this level of care available domestically.
Until then, the research continues — and the veterans keep coming.